DnaNudge, Laronde, DiCE Molecules
Cardior Raises €64M in Series B Funding
Cardior Pharmaceuticals, a Hanover, Germany-based clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, closed a €64m ($76m) Series B financing round.
The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMedPartners, Bristol Myers Squibb and High-Tech Gründerfonds.
The company intends to use the funds for the late-stage clinical development of its lead program and the expansion of its earlier-stage pipeline.
Led by Dr. Claudia Ulbrich, Chief Executive Officer and Co-Founder, Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company advancing the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart.
Cardior Raises €64M in Series B Funding - FinSMEs
Cardior Pharmaceuticals, a Hanover, Germany-based clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, closed a €64m ($76m) Series B financing round
DnaNudge Raises $60M in Series A Funding
DnaNudge, a London UK-based company focused on genetics testing and medical diagnostics, raised $60M in Series A funding.
The round was led by Ventura Capital with participation from Bank Julius Baer.
The company intends to use the funds to to accelerate the deployment of its rapid genetic testing solutions, including the sample-to-result RT-PCR COVID-19 test (‘CovidNudge’), which is in use in healthcare settings around the world.
Led by co-fouder and CEO Chris Toumazou, DnaNudge leverages consumers’ own DNA plus lifestyle factors to nudge people towards healthier choices while shopping. The DnaNudge Nutrition service analyses and maps users’ genetic profile to key nutrition-related health traits such as obesity, diabetes, hypertension and cholesterol, enabling customers to be guided by their DNA towards healthier eating.
DnaNudge Raises $60M in Series A Funding - FinSMEs
DnaNudge, a London UK-based company focused on genetics testing and medical diagnostics, raised $60M in Series A funding.
Tissium Raises €50M in Series C Financing
Tissium, a Paris, France- and Boston, MA-based medtech company developing biomorphic programmable polymers for tissue reconstruction, raised €50M in Series C financing.
The round was led by Cathay Health, affiliated to global investment firm Cathay Capital, with participation from existing shareholders Sofinnova Partners, and others.
The company intends to use the funds to continue to execute on its development plan, up to the commercialization of its nerve repair, hernia repair and cardiovascular sealant products.
Led by Christophe Bancel, CEO, Tissium is a medtech company that is dedicated to the development and commercialization of a portfolio of solutions that leverage its proprietary family of fully biosynthetic, biomorphic and programmable polymers.
Tissium Raises €50M in Series C Financing
Tissium, a Paris, France- and Boston, MA-based medtech company developing biomorphic programmable polymers for tissue reconstruction, raised €50M in Series C financing
Abtrace Raises £2.1M in Seed Funding
Abtrace, a London UK-based healthtech startup, raised £2.1M in seed funding.
The round was led by Faber with participation from Ganexa Capital.
The company intends to use the funds to roll the technology out to new GP practices across the UK and expand their engineering and data science teams.
Led by co-founder and CEO Dr Umar Naeem Ahmad, Abtrace uses machine learning to provide advanced digital solutions that allow healthcare professionals to react and manage the patient’s current diseases and to recognize the first clinical signs of new conditions.
The company has built an AI tool which can plug-into the Electronic Health Record (EHR) database and identify which tests or treatments a patient with a long-term health condition needs or might benefit from.
Abtrace Raises £2.1M in Seed Funding - FinSMEs
Abtrace, a London UK-based healthtech start-up, Raised £2.1M in seed funding led by Faber with participation from Ganexa Capital
Laronde Raises $440M in Series B Financing
Cambridge, Mass.-based company advancing Endless RNA™ (eRNA) – a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body, raised $440M in Series B financing.
The round included the company’s founder, Flagship Pioneering, along with funds and accounts advised by T. Rowe Price Associates, Inc., Invus, Canada Pension Plan Investment Board (CPP Investments), Fidelity Management & Research Company, funds and accounts managed by BlackRock, and Federated Hermes Kaufmann Funds, among others.
The company intends to use the funds to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories.
Founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering, Laronde is advancing Endless RNA™ (eRNA), which, invented at Flagship Labs, is an engineered RNA that can be programmed to express diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery. The company is scaling to support the parallel development of multiple programs across many disease areas.
Laronde Raises $440M in Series B Financing - FinSMEs
Laronde, a Cambridge, Mass.-based company advancing Endless RNA™ (eRNA) – a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body, raised $440M in Series B financing
Atavistik Bio Raises $60M in Series A Financing
Atavistik Bio, a Cambridge, Mass.-based pre-clinical biotechnology company, completed a $60m Series A financing round.
The round was led by The Column Group which was joined by Lux Capital, and Nextech Invest, Ltd.
The company intends to use the funds for the development of its drug discovery platform, and future identification of select drug candidates based on deep knowledge of disease relevant pathways that have evolved over millions of years by nature to be allosterically regulated by metabolites.
Atavistik Bio is pioneering the identification of metabolite-protein interactions that have the potential to lead to the discovery and development of first-in-class drug candidates powered by distinct allosteric control mechanisms.
Atavistik Bio Raises $60M in Series A Financing
Atavistik Bio, a Cambridge, Mass.-based pre-clinical biotechnology company, completed a $60m Series A financing round
DiCE Molecules Raises $60M in Series C-1 Financing
DiCE Molecules, a San Francisco, CA-based biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, completed its $60m Series C-1 financing.
The round was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital, as well as existing investors Northpond Ventures, Eventide Asset Management, etc.
The company, which has raised approximately $200m to date, intends to use the funds to advance its preclinical IL-17 antagonist franchise into clinical development, its preclinical α4ß7 and αVß1/αVß6 integrin programs, expand its pipeline, and for other general corporate purposes.
DiCE Molecules is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas.
DiCE Molecules Raises $60M in Series C-1 Financing
DiCE Molecules, a San Francisco, CA-based biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, completed its $60m Series C-1 financing.
AllStripes Raises $50M in Series B Financing
AllStripes, a San Francisco, CA-based healthcare technology company dedicated to advancing treatments for people affected by rare diseases, raised $50m in Series B financing.
The round was led by Lux Capital, joined by JAZZ Venture Partners, Spark Capital, Medidata Solutions (a Dassault Systèmes company), McKesson Ventures, and Maveron, along with angel investors including Arif Nathoo, CEO of Komodo Health, and Leila Zegna, Director of the Kabuki Syndrome Foundation.
The company intends to use the funds to:
launch 100 new rare disease research programs
expand global operational presence, technology and data automation enhancements to improve research insights,
develop the platform capabilities to enhance the user experience and strengthen the life sciences offerings, and
continue to invest in growing the team to support creating the playbook for rare disease research.
Founded by CEO Nancy Yu and technology developer Onno Faber, following his diagnosis and journey with the rare disease neurofibromatosis type 1, AllStripes is a healthcare technology company dedicated to advancing new treatments for people with rare diseases.
AllStripes Raises $50M in Series B Financing
AllStripes, a San Francisco, CA-based healthcare technology company dedicated to advancing treatments for people affected by rare diseases, raised $50m in Series B financing
Overjet Raises $27M in Series A Funding
Overjet, a Boston MA-based dental artificial intelligence company, raised $27M in Series A funding.
The round was led by General Catalyst and Insight Partners with participation from Crosslink Capital and the MIT-affiliated E14 Fund.
The company, which has raised over $35m to date, intends to use the funds to accelerate market adoption and new product launches.
Led by CEO and Co-founder Dr. Wardah Inam, and COO Shaju Puthussery, Overjet provides dental artificial intelligence, enabling both payers and providers to improve patient care. The company’s dental AI products are designed to allow dentists to deliver the best patient care and enable dental insurers to operate more accurately and efficiently.
Overjet Raises $27M in Series A Funding - FinSMEs
Overjet, a Boston MA-based company focused on dental artificial intelligence, raised $27M in Series A funding.
Triad Life Sciences Closes A$25M Funding
Triad Life Sciences, a Memphis, Tenn.-based biotech company, raised AUS$25m funding round.
The convertible note placement was led by Cannacord Genuity.
The company intends to use the funds for its US sales force expansion plans, R&D activities, and general working capital needs. Triad now plans to move forward with a listing on the Australian Securities Exchange (ASX) in the coming months.
Led by CEO Russ Olsen, Triad Life Sciences is a biotech company focused on developing and commercializing biomaterials for treating complex surgical and chronic wounds. Triad recently received FDA clearance to market InnovaMatrix™, a next generation extracellular matrix (ECM) wound care device.
Triad Life Sciences Closes A$25M Funding
Triad Life Sciences, a Memphis, Tenn.-based biotech company, raised AUS$25m funding round
Equum Medical Raises $20M in Growth Equity Funding
Equum Medical, a NYC-based provider of acute care telehealth and teleICU solutions, raised $20m in growth equity funding.
Heritage Group made the investment.
The company intends to use the funds to further enhance its service model and broaden the reach of its team of clinicians across the United States and beyond.
Led by CEO Corey Scurlock, M.D., Brian Rosenfeld, M.D., executive vice president, Equum Medical brings together an experienced team of clinicians with advanced, data-driven change management methodologies to provide high-touch telehealth services in a flexible manner.
Equum Medical Raises $20M in Growth Equity Funding
Equum Medical, a NYC-based provider of acute care telehealth and teleICU solutions, raised $20m in growth equity funding
Checkpoint Surgical Raises $16M in Equity Funding
Checkpoint Surgical, Inc., a Cleveland OH-based medical device company with proprietary neurostimulation technology for nerve protection and repair, raised $16M in equity funding.
The round was led by River Cities Capital with participation from Mutual Capital Partners, JumpStart NEXT Fund, First Analysis, and several other investors.
The company intends to use the funds for sales force expansion and multiple new product launches, including the recently acquired NeuroShield nerve wrap, as well as continue to conduct research and development activities.
Led by President & CEO Len Cosentino, Checkpoint Surgical is a medical device company that works alongside surgeons to advance the science and practice of peripheral nerve care through research, education and innovative product development. Its nerve stimulation devices inform intraoperative decision making to allow surgeons to safely and effectively protect, assess and repair motor nerves during surgery.
Checkpoint Surgical Raises $16M in Equity Funding - FinSMEs
Checkpoint Surgical, Inc., a Cleveland OH-based medical device company, raised $16M in Equity funding.
Recuro Health Raises $15M in Series A Funding
Recuro Health, a Dallas, TX-based integrated digital health solutions company, raised $15m in Series A financing.
The round was led by ARCH Venture Partners, with participation from OLSF Ventures, Cortado Ventures, 1843 Capital and Sage Venture Partners.
The company intends to use the funds to execute its ongoing acquisition and expanded marketing strategy, as well as to further build upon growth since the launch in March 2021.
Led by Michael Gorton, CEO and founder, Recuro Health is an integrated digital health solution that delivers value throughout the healthcare ecosystem as care moves from traditional office in-person settings to wherever the patient and data are located. The company’s virtual health platform consists of a curated suite of digital solutions, from primary care and behavioral health to at-home testing and genetic screening.
Recuro Health Raises $15M in Series A Funding
Recuro Health, a Dallas, TX-based integrated digital health solutions company, raised $15m in Series A financing
Antidote Health Raises $12M in Seed Funding
Antidote Health, a NYC-based telehealth provider making quality healthcare accessible to all Americans, raised $12m in seed funding.
The round was led by iAngels, Well-Tech Ventures and Flint Capital, along with other angel investors.
The company intends to use the funds to expand nationwide and accelerate its marketing initiatives to further educate potential users of their healthcare options.
Launched in January 2021 by Avihai Soudri, Co-founder and CE=, Antidote Health is a B2C company that provides uninsured and underinsured Americans with an AI-based virtual Health maintenance organization (HMO). via Artificial Intelligence that connects users to doctors with a smart chatbot and through video calls. It provides individuals premium quality health coverage for as little as $29 per month.
Antidote Health Raises $12M in Seed Funding
Antidote Health, a NYC-based telehealth provider making quality healthcare accessible to all Americans, raised $12m in seed funding
Doctor Anywhere Raises US$65.7M in Series C Financing
Doctor Anywhere, a Singapore-based regional tech-led healthcare company, raised US$65.7M in Series C financing.
The round was led by Asia Partners and also joined by Novo Holdings A/S, Philips Venture, OSK-SBI Ventures and existing investors Square Peg, EDBI, IHH Healthcare, Kamet Capital and Pavilion Capital.
The company intends to use the funds to bolster its market leadership, to further deepen its presence in its existing markets, and to expand into new markets.
Led by Lim Wai Mun, Founder and Chief Executive Officer, Doctor Anywhere combines technology and innovation to provide a digital platform that enables patients to access medical assistance on-demand anytime, without leaving their homes, whilst its offline platform provides users with access to resources such as GP clinics and mobile healthcare services.
Doctor Anywhere Raises US$65.7M in Series C Financing
Doctor Anywhere, a Singapore-based regional tech-led healthcare company, raised US$65.7M in Series C financing.
Lynk Pharmaceuticals Closes $50M Series B Financing
Lynk Pharmaceuticals CO., LTD, a Hangzhou, China-based pharmaceutical R&D company, completed Series B financing of $50m.
The round was led by Lilly Asia Ventures (LAV) with participation from New Alliance Capital and Hangzhou HEDA Biological Medicine Venture Capital Partnership (L.L.P.) and its original shareholders Legend Capital and Med-Fine Capital.
The company intends to use the funds to conduct Phase I and II clinical trials for multiple programs in the R&D pipeline, expand international business, strengthen international collaborations with companies and support preclinical development of new projects.
Founded in 2018 and led by Dr. Zhao-Kui (ZK) Wan, Chairman and CEO, Lynk Pharmaceuticals is a drug R&D company dedicated to the development of global FIC/BIC small molecule drugs for autoimmune diseases, inflammation and cancers.